James Boylan is the founder of Enavate Sciences. Enavate Sciences has raised $300M in total funding. Latest round: Seed. Backed by Patient Square Capital.
James Boylan is the Chief Executive Officer of Enavate Sciences, a biotech investment firm launched in May 2022 with $300 million from Patient Square Capital. He leads Enavate's portfolio investments, including leading CAMP4 Therapeutics' $100 million Series B round in 2022 and backing Graviton Bioscience in 2024.
Full founder directory · Investor directory · Company funding database · Fundraising library